echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Impact of postoperative adjuvant therapy on the prognosis of limited-stage small cell lung cancer (SCLC)

    Front Oncol: Impact of postoperative adjuvant therapy on the prognosis of limited-stage small cell lung cancer (SCLC)

    • Last Update: 2021-09-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Small cell lung cancer (SCLC) is divided into limited stage and extensive stage


    Small cell lung cancer (SCLC) is divided into limited stage and extensive stage


    The study included patients who were histologically confirmed to have surgical resection of small cell lung cancer between November 2006 and June 2019


    The study included patients who were histologically confirmed to have surgical resection of small cell lung cancer between November 2006 and June 2019


    The study included 153 patients, most of whom were over 60 years old (65%), male (84%), and smoking history (76%)


    The 5-year survival rates of the non-adjuvant therapy group, adjuvant chemotherapy group, and adjuvant radiotherapy group were 20.



     Comparison of OS with different adjuvant treatments in the general population

    For patients with pT1 stage, there is no statistical difference between the three treatment modalities


    For patients with pT1 stage, there is no statistical difference between the three treatment modalities



    Comparison of OS in different adjuvant treatments in subgroups



    For patients with mixed SCLC, there is no statistical difference between the three treatment modalities




    In summary, studies have shown that for patients with pT2-4 stage and simple SCLC, postoperative adjuvant chemotherapy and radiotherapy can improve the prognosis


    Original source:

    Li D, Deng C, Zheng Q, et al (2021) Impact of Adjuvant Therapy on Survival in Surgically Resected Limited-Stage Small Cell Lung Cancer.
    Front.
    Oncol.
    11:704517.
    doi: 10.
    3389/fonc.
    2021.
    704517

    Li D, Deng C, Zheng Q, et al (2021) Impact of Adjuvant Therapy on Survival in Surgically Resected Limited-Stage Small Cell Lung Cancer.
    Front.
    Oncol.
    11:704517.
    doi: 10.
    3389/fonc.
    2021.
    704517

     

     

     



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.